New insights into myeloid-derived suppressor cells and their roles in feto-maternal immune cross-talk

Journal of Reproductive Immunology

Volumn 113, Issue , 2016, Pages 35-41

  Zhao, Ai Min ^a   Xu, Hai Jing ^a   Kang, Xiao Min ^a   Lu, Li Ming ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Feto maternal cross talk; Immunosuppression; Myeloid derived suppressor cells; Pregnancy

Indexed keywords

CELL DIFFERENTIATION; CELL EXPANSION; FEMALE; FETUS; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; INTRAUTERINE GROWTH RETARDATION; LYMPHOCYTE FUNCTION; MYELOID DERIVED SUPPRESSOR CELL; NEWBORN; NONHUMAN; PASSIVE IMMUNIZATION; PHENOTYPE; PREECLAMPSIA; PREGNANCY COMPLICATION; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; SPONTANEOUS ABORTION; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; BONE MARROW CELL; FETOMATERNAL TRANSFUSION; IMMUNOLOGY; PATHOLOGY; PREGNANCY; TH2 CELL; TROPHOBLAST;

FEMALE; HUMANS; MATERNAL-FETAL EXCHANGE; MYELOID CELLS; PREGNANCY; PREGNANCY COMPLICATIONS; TH2 CELLS; TROPHOBLASTS;

EID: 84960428693     PISSN: 01650378     EISSN: 18727603     Source Type: Journal    
DOI: 10.1016/j.jri.2015.11.001     Document Type: Review

References (105)

1. Abrahams V.M., Mor G. Toll-like receptors and their role in the trophoblast. Placenta 2005, 26:540-547.
2. Abrahams V.M., et al. A role for TLRs in the regulation of immune cell migration by first trimester trophoblast cells. J. Immunol. 2005, 175:8096-8104.
3. Alabanza L.M., et al. Inhibition of endogenous activated protein C attenuates experimental autoimmune encephalomyelitis by inducing myeloid-derived suppressor cells. J. Immunol. 2013, 191:3764-3777.
4. Arck P.C., Hecher K. Fetomaternal immune cross-talk and its consequences for maternal and offspring's health. Nat. Med. 2013, 19:548-556.
5. Arocena A.R., et al. Myeloid-derived suppressor cells are key players in the resolution of inflammation during a model of acute infection. Eur. J. Immunol. 2014, 44:184-194.
6. Beury D.W., et al. Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. J. Leukoc. Biol. 2014, 96:1109-1118.
7. Bogovic Crncic T., et al. Perforin and Fas/FasL cytolytic pathways at the maternal-fetal interface. Am. J. Reprod. Immunol. 2005, 54:241-248.
8. Bonney E.A., Brown S.A. To drive or be driven: the path of a mouse model of recurrent pregnancy loss. Reproduction 2014, 147:R153-R167.
9. Buessow S.C., et al. Influence of mammary tumor progression on phenotype and function of spleen and in situ lymphocytes in mice. J. Natl. Cancer Inst. 1984, 73:249-255.
10. Bunt S.K., et al. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 2006, 176:284-290.
11. Bunt S.K., et al. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 2007, 67:10019-10026.
12. Canavan T.P., Simhan H.N. Innate immune function of the human decidual cell at the maternal-fetal interface. J. Reprod. Immunol. 2007, 74:46-52.
13. Cheng P., et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 2008, 205:2235-2249.
14. Condamine T., Gabrilovich D.I. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2011, 32:19-25.
15. Condamine T., et al. Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu. Rev. Med. 2015, 66:97-110.
16. Cuenca A.G., et al. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol. Med. 2011, 17:281-292.
17. Dai J., et al. Myeloid-derived suppressor cells: paradoxical roles in infection and immunity. J. Innate Immun. 2014, 7:116-126.
18. Dan S., et al. Effect of prednisolone administration on patients with unexplained recurrent miscarriage and in routine intracytoplasmic sperm injection: a meta-analysis. Am. J. Reprod. Immunol. 2015, 74:89-97.
19. De Carolis C., et al. War and peace at the feto-placental front line: recurrent spontaneous abortion. Isr. Med. Assoc. J. 2014, 16:667-668.
20. De Wilde V., et al. Endotoxin-induced myeloid-derived suppressor cells inhibit alloimmune responses via heme oxygenase-1. Am. J. Transplant. 2009, 9:2034-2047.
21. Diaz-Montero C.M., et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 2009, 58:49-59.
22. Dilek N., et al. Control of transplant tolerance and intragraft regulatory T cell localization by myeloid-derived suppressor cells and CCL5. J. Immunol. 2012, 188:4209-4216.
23. Drujont L., et al. Evaluation of the therapeutic potential of bone marrow-derived myeloid suppressor cell (MDSC) adoptive transfer in mouse models of autoimmunity and allograft rejection. PLoS One 2014, 9:e100013.
24. Du R., et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13:206-220.
25. Dudley M.E., Rosenberg S.A. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer 2003, 3:666-675.
26. Elami-Suzin M., Mankuta D. Role of natural killer cells in normal pregnancy and recurrent pregnancy loss. Harefuah 2007, 146(164):140-144.
27. Enioutina E.Y., et al. A role for immature myeloid cells in immune senescence. J. Immunol. 2011, 186:697-707.
28. Filipazzi P., et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 2007, 25:2546-2553.
29. Fletcher M., et al. -Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells. Cancer Res. 2015, 75:275-283.
30. Gabitass R.F., et al. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol. Immunother. 2011, 60:1419-1430.
31. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
32. Gallot V., et al. Early recurrent miscarriage:Evaluation and management. J. Gynecol. Obstet. Biol. Reprod. 2014, 43:812-841.
33. Gantt S., et al. The role of myeloid-derived suppressor cells in immune ontogeny. Front. Immunol. 2014, 5(387).
34. Gao L., et al. Characteristics of immune cell changes before and after immunotherapy and their clinical significance in patients with unexplained recurrent spontaneous abortion. Genet. Mol. Res. 2014, 13:1169-1178.
35. Gervassi A., et al. Myeloid derived suppressor cells are present at high frequency in neonates and suppress in vitro T cell responses. PLoS One 2014, 9:e107816.
36. Giudice L.C. Genes associated with embryonic attachment and implantation and the role of progesterone. J. Reprod. Med. 1999, 44:165-171.
37. Gonzalez J.M., et al. Comparison of the mechanisms responsible for cervical remodeling in preterm and term labor. J. Reprod. Immunol. 2013, 97:112-119.
38. Greifenberg V., et al. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur. J. Immunol. 2009, 39:2865-2876.
39. Hegde V.L., et al. Distinct microRNA expression profile and targeted biological pathways in functional myeloid-derived suppressor cells induced by δ9-tetrahydrocannabinol in vivo: regulation of CCAAT/enhancer-binding protein alpha by microRNA-690. J. Biol. Chem. 2013, 288:36810-36826.
40. Heim C.E., et al. IL-12 promotes myeloid-derived suppressor cell recruitment and bacterial persistence during Staphylococcus aureus orthopedic implant infection. J. Immunol. 2015, 194(8):3861-3872.
41. Highfill S.L., et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 2010, 116:5738-5747.
42. Hongo D., et al. Requirement for interactions of natural killer T cells and myeloid-derived suppressor cells for transplantation tolerance. Am. J. Transplant. 2014, 14:2467-2477.
43. Idorn M., et al. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells: regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol. Immunother. 2014, 63:1177-1187.
44. Ilkovitch D., Lopez D.M. The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res. 2009, 69:5514-5521.
45. Ioannou M., et al. In vivo ablation of plasmacytoid dendritic cells inhibits autoimmunity through expansion of myeloid-derived suppressor cells. J. Immunol. 2013, 190:2631-2640.
46. Jin L.P., et al. Regulation of costimulatory signal in maternal-fetal immune tolerance. Am. J. Reprod. Immunol. 2011, 66:76-83.
47. Koch C.A., Platt J.L. Natural mechanisms for evading graft rejection: the fetus as an allograft. Springer Semin. Immunopathol. 2003, 25:95-117.
48. Kollmann T.R., et al. Innate immune function by toll-like receptors: distinct responses in newborns and the elderly. Immunity 2012, 37:771-783.
49. Kostlin N., et al. Granulocytic myeloid derived suppressor cells expand in human pregnancy and modulate T-cell responses. Eur. J. Immunol. 2014, 44:2582-2591.
50. Kowanetz M., et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6g+Ly6c+ granulocytes. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21248-21255.
51. Kujawski M., et al. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 2008, 118:3367-3377.
52. Kwak-Kim J., et al. Recurrent pregnancy loss: a disease of inflammation and coagulation. J. Obstet. Gynaecol. Res. 2009, 35:609-622.
53. Kwak-Kim J., et al. Immunological modes of pregnancy loss. Am. J. Reprod. Immunol. 2010, 63:611-623.
54. Kwak-Kim J., et al. Immunological modes of pregnancy loss: inflammation, immune effectors, and stress. Am. J. Reprod. Immunol. 2014, 72:129-140.
55. Larsen E.C., et al. New insights into mechanisms behind miscarriage. BMC Med. 2013, 11:154.
56. Lash G.E., Ernerudh J. Decidual cytokines and pregnancy complications: focus on spontaneous miscarriage. J. Reprod. Immunol. 2015, 108:83-89.
57. Li Z., et al. Tumor-derived transforming growth factor-beta is critical for tumor progression and evasion from immune surveillance. Asian Pac. J. Cancer Prev. 2014, 15:5181-5186.
58. Liao J., et al. Dexamethasone potentiates myeloid-derived suppressor cell function in prolonging allograft survival through nitric oxide. J. Leukoc. Biol. 2014, 96:675-684.
59. Lissner M.M., et al. Age-related gene expression differences in monocytes from human neonates, young adults, and older adults. PLoS One 2015, 10:e0132061.
60. Liu C., et al. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 2007, 109:4336-4342.
61. Luan Y., et al. Monocytic myeloid-derived suppressor cells accumulate in renal transplant patients and mediate cd4(+) foxp3(+) treg expansion. Am. J. Transplant. 2013, 13:3123-3131.
62. Lv M., et al. Monocytic and promyelocytic myeloid-derived suppressor cells may contribute to G-CSF-induced immune tolerance in haplo-identical allogeneic hematopoietic stem cell transplantation. Am. J. Hematol. 2015, 90:E9-16.
63. Melani C., et al. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003, 102:2138-2145.
64. Menetrier-Caux C., et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998, 92:4778-4791.
65. Mirza N., et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006, 66:9299-9307.
66. Mucha J., et al. MDSCs mediate angiogenesis and predispose canine mammary tumor cells for metastasis via IL-28/IL-28RA (IFN-λ) signaling. PLoS One 2014, 9:e103249.
67. Nair R.R., et al. Reduced myeloid-derived suppressor cells in the blood and endometrium is associated with early miscarriage. Am. J. Reprod. Immunol. 2014, 73:479-486.
68. Nakamura I., et al. Serum levels of vascular endothelial growth factor are increased and correlate with malnutrition, immunosuppression involving MDSCs and systemic inflammation in patients with cancer of the digestive system. Oncol. Lett. 2013, 5:1682-1686.
69. Noman M.Z., et al. PF-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 2014, 211:781-790.
70. Novitskiy S.V., et al. TGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms. Cancer Discov. 2011, 1:430-441.
71. Obermajer N., et al. PGE(2)-induced CXCl12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 2011, 71:7463-7470.
72. Ochoa A.C., et al. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res. 2007, 13:721s-726s.
73. Pak A.S., et al. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin. Cancer Res. 1995, 1:95-103.
74. Pan P.Y., et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008, 111:219-228.
75. Porter D.L., June C.H. T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up!. Bone Marrow Transplant. 2005, 35:935-942.
76. Prabhudas M., et al. Challenges in infant immunity: implications for responses to infection and vaccines. Nat. Immunol. 2011, 12:189-194.
77. Prado C., et al. Dexamethasone upregulates FOXP3 expression without increasing regulatory activity. Immunobiology 2011, 216:386-392.
78. Raghupathy R. Th1-type immunity is incompatible with successful pregnancy. Immunol. Today 1997, 18:478-482.
79. Ragusa A., et al. Progesterone supplement in pregnancy: an immunologic therapy?. Lupus 2004, 13:639-642.
80. Ray A., et al. Immunosuppressive MDSCs induced by TLR signaling during infection and role in resolution of inflammation. Front. Cell. Infect. Microbiol. 2013, 3(52).
81. Rieber N., et al. Neutrophilic myeloid-derived suppressor cells in cord blood modulate innate and adaptive immune responses. Clin. Exp. Immunol. 2013, 174:45-52.
82. Rodriguez P.C., Ochoa A.C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol. Rev. 2008, 222:180-191.
83. Rodriguez P.C., et al. l-Arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007, 109:1568-1573.
84. Rodriguez P.C., et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009, 69:1553-1560.
85. Rudolph B.M., et al. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients. Exp. Dermatol. 2014, 23:202-204.
86. Sade-Feldman M., et al. Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity 2013, 38:541-554.
87. Safinia N., et al. Promoting transplantation tolerance; adoptive regulatory T cell therapy. Clin. Exp. Immunol. 2013, 172:158-168.
88. Saito S., Nakashima A. A review of the mechanism for poor placentation in early-onset preeclampsia: the role of autophagy in trophoblast invasion and vascular remodeling. J. Reprod. Immunol. 2014, 101-102:80-88.
89. Schlecker E., et al. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate ccr5-dependent recruitment of regulatory T cells favoring tumor growth. J. Immunol. 2012, 189:5602-5611.
90. Serafini P., et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 2006, 203:2691-2702.
91. Serafini P. Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly. Immunol. Res. 2013, 57:172-184.
92. Sinha P., et al. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007, 67:4507-4513.
93. Staff A.C., et al. Preeclampsia and uteroplacental acute atherosis: Immune and inflammatory factors. J. Reprod. Immunol. 2014, 101-102:120-126.
94. Talmadge J.E., Gabrilovich D.I. History of myeloid-derived suppressor cells. Nat. Rev. Cancer 2013, 13:739-752.
95. Talmadge J.E., et al. Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. Int. Immunopharmacol. 2007, 7:140-151.
96. Tebartz C., et al. A major role for myeloid-derived suppressor cells and a minor role for regulatory T cells in immunosuppression during Staphylococcus aureus infection. J. Immunol. 2014, 194:1100-1111.
97. Tsukamoto H., et al. Myeloid-derived suppressor cells attenuate Th1 development through IL-6 production to promote tumor progression. Cancer Immunol. Res. 2013, 1:64-76.
98. Verschoor C.P., et al. Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer. J. Leukoc. Biol. 2013, 93:633-637.
99. Wallace A.E., et al. Extravillous trophoblast and decidual natural killer cells: a remodelling partnership. Hum. Reprod. Update 2012, 18:458-471.
100. Wegmann T.G., et al. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a Th2 phenomenon?. Immunol. Today 1993, 14:353-356.
101. Weiss J.M., et al. Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapy. J. Immunol. 2014, 192:5821-5829.
102. Yang L., et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008, 13:23-35.
103. Zhang H., et al. Fibrocytes represent a novel mdsc subset circulating in patients with metastatic cancer. Blood 2013, 122:1105-1113.
104. Zhang L., et al. Myeloid-derived suppressor cells protect mouse models from autoimmune arthritis via controlling inflammatory response. Inflammation 2014, 37:670-677.
105. Zhu B., et al. CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J. Immunol. 2007, 179:5228-5237.